UW Research
Frequently-Asked Questions

New Industry Clinical Trial Definition and F&A Rate Effective July 1st

Q1: I am talking with a company about running a clinical trial and will start the process in REDCap ahead of eGC1 routing. Should I use the 35% rate now, since I am submitting budget related information to CTO and talking to the sponsor?
A1: Use the 35% TDC rate if you plan on routing the eGC1 on or after July 1st, 2025. If routing the eGC1 before then, please use the 27% TDC rate.

Q2: I have an eGC1 in approved status but the Clinical Trial Agreement is under negotiation or may not be fully executed before July 1st. Will I need to update my budget and /renegotiate the rate, or can I continue to use the 27% TDC rate?
A2: For eGC1s already in routing, IN OSP, or approved as of June 30th, 2025, use the 27% TDC rate.

Q3: I anticipate an amendment to my CTA. Do I need to apply the 35% TDC rate to the additional amount we will be billing once the amendment is approved?
A3: No, supplements continue to use the rate used at the time the initial CTA was signed.

Q4: I am concerned industry partners will not consider UW/FHCC as a site with this increased rate. How was this rate determined?
A4: This rate was established to bring us in line with peer institutions, including medical centers, and the associated costs of running clinical trials.

Q5: When does the eGC1 status change to “Completed” and where can I see when an eGC1 was “Completed”?
A5: An eGC1 is considered “completed” after the PI certifies and routes the eGC1. This is visible in the History & Comments section of an eGC1 in SAGE.

Resources